Chai Discovery, an AI-native biotech startup backed by OpenAI, has closed a $130 million Series B financing at a $1.3 billion valuation, bringing total funding to more than $225 million. The round was led by General Catalyst and Oak HC/FT, with participation from Menlo Ventures, OpenAI, Thrive Capital, SV Angel, Dimension, Neo, Yosemite, Lachy Groom, and new investors Glade Brook and Emerson Collective.
Founded in 2024 by Josh Meier, Chai is developing foundation models purpose-built for drug discovery, focusing on predicting and designing molecular interactions. The company recently introduced Chai 2, reporting improved success rates in de novo antibody design compared with existing approaches. The new capital will accelerate model development as Chai pursues its goal of building a computer-aided design suite for molecules.
Featured image: Credit: Chai Discovery
